tirzepatide fda compounding pharmacy Tirzepatide, FDA, and Compounding: Understanding the Current Landscape Compounded Tirzepatide (GLP-1/GIP)

Novo Nordisk originally developed the active ingredient semaglutide for the treatment of type 2 diabetes

To reduce skin sensitivity, ensure you rotate the injection sites, use a clean needle for each injection, and avoid injecting into areas with scars or moles

That delay gives colonic bacteria more substrate to ferment, increasing production of hydrogen, methane, and carbon dioxide

With diagnosed diabetes affecting an estimated 3.9 million Canadians and Canada recognised as the worlds second-largest market for semaglutide, immediate availability is expected to be a meaningful differentiator for patients, payers and the healthcare system